Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

30.94 +0.34 (+1.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alkermes Plc

< Previous 1 2 3 4 5 6 7 8 Next >
Earnings Preview: Alkermes
Via Benzinga
Where Alkermes Stands With Analysts
Via Benzinga
Alkermes Raises FY23 Outlook Following Arbitration Award from Janssen Agreements
Via Benzinga
Alkermes Earnings Perspective: Return On Capital Employed
Via Benzinga
Analyst Expectations for Alkermes's Future
Via Benzinga
The Latest Analyst Ratings for Alkermes
Via Benzinga
A Preview Of Alkermes's Earnings
Via Benzinga
Alkermes Stock Sees Rising Relative Strength Rating
The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77. 
Via Investor's Business Daily
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Alkermes Earnings Preview
Via Benzinga
Analyst Ratings for Alkermes
Via Benzinga
Alkermes Plans Separating Its Oncology Unit; Lifts FY22 Earnings Guidance
Via Benzinga
Recap: Alkermes Q2 Earnings
  Alkermes (NASDAQ:ALKS) reported its Q2 earnings results on Wednesday, July 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Alkermes: Commercialization Program On Track, Sales Coming In Strong
The bigger biotechs have done a good job lately, with solid earnings to date. Speaking of which, Alkermes plc has recently exceeded estimates. Let's take a closer look at the company's performance. 
Via Talk Markets
Alkermes Stock Sees Rising Relative Price Strength
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86. 
Via Investor's Business Daily
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out
Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev. 
Via Investor's Business Daily
Alkermes's Return On Capital Employed Insights
Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q3 sales of $252.36 million. Earnings fell to a loss of $63.97 million, resulting in a 112.28% decrease from last quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
Upgrades 
Via Benzinga
Recap: Alkermes Q3 Earnings
Alkermes (NASDAQ:ALKS) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Alkermes missed estimated... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022
Upgrades 
Via Benzinga
Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday
Wedbush raised Domino's Pizza, Inc. (NYSE: DPZ) price target from $370 to $400. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Domino's shares rose 10.4% to close at $333.26... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022
  
Via Benzinga
Looking Into Alkermes's Return On Capital Employed
According to data from Benzinga Pro, during Q2, Alkermes's (NASDAQ:ALKS) reported sales totaled $276.22 million. Despite a 16.06% increase in earnings, the company posted a loss of $30.14 million. 
Via Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Preview: Alkermes
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-07-27. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will... 
Via Benzinga
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
Northrop Grumman Leads 5 Defensive Plays Near Buy Points
Northrop headlines 5 stocks near buy points with the mettle to withstand a recession. 
Via Investor's Business Daily
Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade
Day One Biopharmaceuticals stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 83 to 92. 
Via Investor's Business Daily
4 Biotech Stocks With Bright Prospects To Buy Amid Recovery
New drug approvals, acquisitions, and other pipeline developments are back in the spotlight in the biotech industry, following the focus on the development of vaccines and antibody treatments for... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.